Celyad Oncology SA is a clinical-stage biotechnology company headquartered in Mont-Saint-Guibert, Belgium, specializing in the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer treatment. The company focuses on both allogeneic and autologous CAR T candidates targeting hematological malignancies and solid tumors, leveraging proprietary technology platforms and intellectual property to address limitations in current therapies. Key product candidates include CYAD-101, an NKG2D receptor-based allogeneic CAR T using non-gene edited TIM technology for refractory metastatic colorectal cancer; CYAD-211, a short hairpin RNA-based allogeneic CAR T for relapsed or refractory multiple myeloma; and CYAD-02, an autologous NKG2D CAR T for relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. With a lean team of around 18 employees, Celyad Oncology SA emphasizes strategic partnerships and innovation to advance next-generation immunotherapies, playing a role in the evolving landscape of oncology biotechnology by broadening treatment options for challenging cancer indications.